|
|
9/19/2006 9:22:52 AM ET
SWISS MEDICA IS RANKED #3 IN PROFIT MAGAZINE’S HOT 50 CANADIAN EMERGING GROWTH COMPANIES
FOR IMMEDIATE RELEASE
Stock Symbol: OTC BB: SWME
September 19, 2006
Toronto, Canada – Swiss Medica, Inc. (OTC BB: SWME) is pleased to announced that it has been ranked # 3 in
the top 50 emerging growth companies in Canada according to the 7th annual PROFIT HOT 50 ranking. The
PROFIT HOT 50 is the definitive ranking of Canada’s emerging growth companies and is published in the
October 2006 issue of “PROFIT: Your Guide to Business Success” and online at www.profitguide.com. The
PROFIT HOT 50 ranks young firms by two-year revenue growth.
According to Ian Portsmouth, editor of PROFIT, “The PROFIT HOT 50 companies represent the ambition,
sophistication and immense contribution of Canada’s entrepreneurial sector. PROFIT is proud to celebrate the
success of these businesses and to share their growth strategies.”
“I am extremely grateful to our employees, customers, shareholders and other stakeholders who have supported
our vision of commercializing elite over-the-counter, patented all natural products for chronic ailments. We
believe that we are still very early in the product acceptance cycle for science-based over-the-counter products
for chronic ailments and increasing concerns about side effects from prescription drugs will allow Swiss Medica’s
patented products to continue to gain significantly more acceptance from consumers and the medical community
in North America and throughout the world”, said Raghu Kilambi, CEO of Swiss Medica Inc.
About PROFIT: Your Guide to Business Success
PROFIT: Your Guide to Business Success, offers news, strategies, tips, interviews and other recourses to the
CEOS of Canadian growth companies. Each year, PROFIT, which currently reaches more than 370,000 readers
nationally, hosts a number of events that bring together business leaders in the fast-growth segments and
champions the interests oft hose leaders. PROFIT was founded in April 1982 as Canada’s first national
magazine geared to entrepreneurs. Visit PROFITguide.com.
About Swiss Medica, Inc.
Swiss Medica is a specialty pharmaceutical company focused on commercializing over-the-counter clinically-
tested, patented all-natural products that relieve chronic ailments. Swiss Medica builds its brands through
innovative and focused distribution and marketing strategies. Swiss Medica's mission is to be a world leader in
the commercialization of over-the-counter, safe and effective chronic ailment treatments. Please visit our
websites at www.swissmedica.com, www.O24zone.com and www.pmsescape.com.
Swiss Medica's flagship product, the O24™ Pain Neutralizer, holds US Patent #6,444,238B1. The O24™ pain
relief solution has been used and recommended for its fast-acting and long-lasting benefits by healthcare
professionals and athletes in the United States, Canada and in Europe. O24™ is widely available over-the-
counter throughout the United States and Canada in leading pharmacies and other retailers. Customers can
also visit www.O24zone.com, for ordering details and store locators for the nearest pharmacy.
Swiss Medica has recently launching the patented O24 Fibromyalgia™ pain reliever (US Patent #6,444,238B1)
over-the-counter in North American retailers. The National Fibromyalgia Association (NFA) recently awarded
O24 Fibromyalgia™ their first NFA Seal of Approval. Over 10 million Americans suffer from the long-term pain
associated with fibromyalgia. In a randomized double blind clinical trial conducted in 2005, 88 per cent of the
patients who used O24 Fibromyalgia™ reported mild to markedly better improvement, versus only 7 per cent
who used the placebo. Customers can also visit www.O24zone.com for ordering details and store locators for the
nearest retailer.
Swiss Medica also distributes PMS Escape® which holds US Patent #'s 5760014 and 5612320. PMS Escape® is
a specially formulated group of carbohydrates, vitamins and minerals, clinically proven to reduce changes in
mood and appetite that women experience during the premenstrual period. Customers can also visit:
www.pmsescape.com for additional information and ordering details.
Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the
United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking
statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close
transactions being contemplated, risks related to international sales and potential foreign currency exchange
fluctuations, continued acceptance of Swiss Medica's products, increased levels of competition, technological
changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica's
periodic reports filed with the United States Securities and Exchange Commission and other regulatory
authorities.
For more information, please contact:
Swiss Medica, Inc.
Investor Relations Contact:
David Jones
1-866-485-4243
djones@swissmedica.com
|
|
